Biofil Chemicals and Pharmaceuticals Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Biofil Chemicals and Pharmaceuticals Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 95% of Healthcare companies in India.
- Profit Cash Ratio: Over the last 3 years, every ₹100 of reported profit came with ₹-3 of operating cash. Lower than 93% of Healthcare companies in India.
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 92% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹-3Over the last 3 years, every ₹100 of reported profit came with ₹-3 of operating cash.
Lower than 93% of Healthcare companies in India.
Self-Funding Ratio
-0.4×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 95% of Healthcare companies in India.
Cash Locked Ratio
₹50For every ₹100 of sales, ₹50 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹29 tied up three years earlier.
More money tied up than 92% of Healthcare companies in India.
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Less steady than 84% of Healthcare companies in India.
Growth Efficiency Ratio
—Sales fell 5%
Sales fell 5% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-5% / +36%In 3 years sales changed by -5% while total assets changed by +36%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-0.2×Operating cash was negative last year, while some debt falls due within a year.
Lower than 92% of Healthcare companies in India.
Cash Cushion Ratio
+1%Cash, after subtracting all debt, equals 1% of its market value (net cash).
Higher than 62% of Healthcare companies in India.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Biofil Chemicals and Pharmaceuticals Limited owes ₹0.50 for every ₹1 it owns. Net profit rose 400% in the year to Mar 2026, and grew 71% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
170.8Investors pay ₹170.8 for every ₹1 of Biofil Chemicals and Pharmaceuticals Limited's yearly profit, higher than 97% of Healthcare companies in India.
P/B ratio
2.19The share price is 2.19 times Biofil Chemicals and Pharmaceuticals Limited's book value per share, lower than 85% of Healthcare companies in India.
Market cap
₹47 CrThe total market value of all of Biofil Chemicals and Pharmaceuticals Limited's shares at today's price (share price × number of shares), smaller than almost all Healthcare companies in India. PosiCap size class: Nano Cap.
Net worth (book value)
₹22 CrWhat Biofil Chemicals and Pharmaceuticals Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹13.25Net worth divided by the number of shares. The share price of ₹29.04 is 2.2 times this, which is the P/B above.
Return on equity (ROE)
1.3%Biofil Chemicals and Pharmaceuticals Limited earned 1.3% on its shareholders' money over the last year, lower than 90% of Healthcare companies in India.
Owes vs Owns
0.50×Biofil Chemicals and Pharmaceuticals Limited owes ₹0.50 for every ₹1 it owns (low), higher than 83% of Healthcare companies in India.
Dividend yield
NoneBiofil Chemicals and Pharmaceuticals Limited does not currently pay a dividend.
Revenue growth
-15%Revenue fell 15% in the year to Mar 2026, and shrank 2% a year on average over 3 years.
Profit growth
+400%Net profit rose 400% in the year to Mar 2026, and grew 71% a year on average over 3 years.
Profit margin
9.8%Biofil Chemicals and Pharmaceuticals Limited keeps ₹10 of every ₹100 of revenue as net profit.
Cash quality
-0.2×Cash from Biofil Chemicals and Pharmaceuticals Limited's business was -0.2× its reported profit in the year to Mar 2026 — the business used cash even though it reported a profit.
Interest cover
41.5×Biofil Chemicals and Pharmaceuticals Limited's operating profit covered its interest costs 41.5 times in the year to Mar 2026.
Cash vs debt
Net cashBiofil Chemicals and Pharmaceuticals Limited held ₹0 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is Biofil Chemicals and Pharmaceuticals Limited's P/E ratio?
Investors pay ₹170.8 for every ₹1 of Biofil Chemicals and Pharmaceuticals Limited's yearly profit, higher than 97% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Biofil Chemicals and Pharmaceuticals Limited: ₹47 Cr ÷ ₹22 Cr (31 Mar 2026) = 2.2.
What is Biofil Chemicals and Pharmaceuticals Limited's return on equity?
Biofil Chemicals and Pharmaceuticals Limited earned 1.3% on its shareholders' money over the last year, lower than 90% of Healthcare companies in India.
How much does Biofil Chemicals and Pharmaceuticals Limited owe compared with what it owns?
Biofil Chemicals and Pharmaceuticals Limited owes ₹0.50 for every ₹1 it owns (low), higher than 83% of Healthcare companies in India.
Does Biofil Chemicals and Pharmaceuticals Limited pay a dividend?
No. Biofil Chemicals and Pharmaceuticals Limited does not currently pay a dividend.
Is Biofil Chemicals and Pharmaceuticals Limited's revenue growing?
Revenue fell 15% in the year to Mar 2026, and shrank 2% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.